EXPERIENCE WITH COMBINATION VAGINAL AGENTS USED IN THE TREATMENT OF MIXED VAGINOSIS/VAGINITIS IN POSTMENOPAUSAL WOMEN

Objective. To evaluate the efficiency of a 2-step combination therapy cycle (broad-spectrum and local combined vaginal agents and probiotics) for mixed vaginosis/vaginitis in women during the menopausal transition and postmenopause in terms of patients’ subjective complaints. Subjects and methods. The prospective investigation included 28 women aged 53 to 65 years who had complaints of discomfort in the external genital area, such as itching, leucorrhoea, and unpleasant odour. All the patients underwent clinical, laboratory, overall and gynecological examinations. The femoflor test was used as a diagnostic one to study the vaginal microbial composition. The therapy of dysbiosis consisted of 2 steps: 1) the combined drug clindacin B prolong was used by the scheme: one intravaginal application of the drug overnight for 3 days (3 packages per treatment cycle) and 2) one intravaginal lactoginal suppository overnight for 14 days. Results. All the respondents reported improvement after the first step of treatment and no recurrences after its second step. Conclusion. Broad-spectrum combined agents demonstrate their efficacy just on the first day of short-term therapy cycles and the use of probiotics may prolong an interrecurrence interval.

menopausal transition, postmenopausal period, vaginal biotope, vaginosis, vaginitis, clindacin B prolong, lactoginal